A Phase 1/2 interventional study of Tisotumab vedotin (HuMax-TF-ADC) in Ovary Cancer, Cervix Cancer and Endometrium Cancer, sponsored by Seagen Inc.. Completed at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-08.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.
Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 22nd largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 1/2, and was the 9th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, France, Korea, Republic of and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 11 · Phase 3 5
First in 2003; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 52 across the 38 interventional studies. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
3 of the studies in Ovarian Neoplasms by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04553133PfizerPF-07104091 as a Single Agent and in Combination Therapy | 2026-12-31 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Ovarian Neoplasms by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
The study is conducted in two parts. In the Dose Escalation portion of the trial, subjects are enrolled into cohorts at increasing dose levels of tisotumab vedotin (HuMax-TF-ADC) in 28 day treatment cycles.
The Cohort Expansion portion of the trial will further explore the recommended phase 2 dose of tisotumab vedotin (HuMax-TF-ADC) as determined in Part 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have according to v1.1
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tisotumab vedotin (HuMax-TF-ADC)
Part 1: Number of Participants Who Experience at Least One Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Part 2: Number of Participants Who Experience at Least One Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE)
A SAE is defined as an AE that met one or more of the following criteria/outcomes which were classified as serious: Required inpatient hospitalization or prolongation of existing hospitalization. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. Was a congenital anomaly/birth defect. Medically important determined by the investigator. Resulted in death. Was life-threatening.
Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Part 2: Number of Participants Reporting One or More Serious Adverse Events (SAE)
A SAE is defined as an AE that met one or more of the following criteria/outcomes which were classified as serious: Required inpatient hospitalization or prolongation of existing hospitalization. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. Was a congenital anomaly/birth defect. Medically important determined by the investigator. Resulted in death. Was life-threatening.
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants Reporting One or More Infusion-related Adverse Events
An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.
Time frame: Day 1, Day 8 & Day 15 (+1 day) until end of treatment (Part 1), approximately 48 weeks
Part 2: Number of Participants Reporting One or More Infusion-related Adverse Events
An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.
Time frame: Day 1, Day 8 & Day 15 (+1 day) until end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events
A CTCAE AE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator.
Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Part 2: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events
A CTCAE AE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator.
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants Reporting One or More Treatment-related Adverse Events
A treatment-related AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; which has a causal relationship with the treatment.
Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events
A treatment-related AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; which has a causal relationship with the treatment.
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants With Markedly Abnormal Laboratory Values
The number of participants with any markedly abnormal standard safety laboratory values collected throughout study. Markedly abnormal laboratory values are defined as any grade \>=3 laboratory abnormality events.
Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Part 2: Number of Participants With Markedly Abnormal Laboratory Values
The number of participants with any markedly abnormal standard safety laboratory values collected throughout study. Markedly abnormal laboratory values are defined as any grade \>=3 laboratory abnormality events.
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants Who Experienced a Skin Rash
Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Part 2: Number of Participants Who Experienced a Skin Rash
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants Who Experienced a Bleeding Event
Time frame: Baseline to end of trial (Part 1), up to 72 weeks
Part 2: Number of Participants Who Experienced a Bleeding Event
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants Who Experienced a Neuropathy Event
Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Part 2: Number of Participants Who Experienced a Neuropathy Event
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8 and 15, + 24 hours 1st infusion (Day 2), + 24 hours 3rd infusion (Day 16), + 72 hours 3rd infusion (Day 18), + 168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Tisotumab Vedotin (HuMax-TF-ADC)
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8 and 15, + 24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), +168 hours 3rd infusion (Day 22) of Cycle 1
Part 1: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Tisotumab Vedotin (HuMax-TF-ADC)
Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.
Time frame: Before infusion of Day 1, 8 and 15 of Cycle 1
Part 1: Terminal Phase Elimination Half-life (T1/2) for Tisotumab Vedotin (HuMax-TF-ADC)
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore t1/2 could not be determined.
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 1: Total Clearance (CL) of Tisotumab Vedotin (HuMax-TF-ADC)
Data is only available for Part 1, for Part 2 inadequate pharmacokinetic samples were collected after the third dose to define a terminal phase, and therefore CL could not be determined.
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 1: Apparent Volume of Distribution (Vz) for Tisotumab Vedotin (HuMax-TF-ADC)
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore Vz could not be determined.
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Total HuMax-TF (Conjugated and Non-conjugated)
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 1: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: Terminal Phase Elimination Half-life (T1/2) for Total HuMax-TF (Conjugated and Non-conjugated)
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore t1/2 could not be determined.
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 1 and Part 2: Total Clearance (CL) of Total HuMax-TF (Conjugated and Non-conjugated)
CL could not be estimated for Part 1 or Part 2 participants due to insufficient number of samples taken.
Time frame: 0 to 2 hours post-dose on days 1, 8, 15, +24 hrs 1st infusion, +24 hrs 3rd infusion, +72 hrs 3rd infusion, +168 hrs 3rd infusion (Part 1) and 0 to 2 hours post-dose on day 1, and pre-dose days 8 and 15 (Part 2) of Cycle 1
Part 1 & Part 2: Apparent Volume of Distribution (Vz) for Total HuMax-TF (Conjugated and Non-conjugated)
Vz could not be estimated for Part 1 or Part 2 participants due to insufficient number of samples taken.
Time frame: 0 to 2 hours post-dose on days 1, 8, 15, +24 hrs 1st infusion, +24 hrs 3rd infusion, +72 hrs 3rd infusion, +168 hrs 3rd infusion (Part 1) and 0 to 2 hours post-dose on day 1, and pre-dose days 8 and 15 (Part 2) of Cycle 1
Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Total HuMax-TF (Conjugated and Non-conjugated)
Data is only available for Part 1, for Part 2, inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.
Time frame: Before infusion on Day 1, 8 and 15 of Cycle 1
Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)
Time frame: Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
Time frame: Before infusion, end of infusion (+15 minutes) and +2 hours post infusion on day 1, and before infusion on days 8 and 15 of Cycle 1
Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Free Toxin (MMAE)
Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.
Time frame: Before infusion on Day 1, 8 and 15 of Cycle 1
Part 1: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result
Time frame: Baseline to end of follow-up; maximum follow-up was 24 weeks
Part 2: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Patients Who Experienced Anti-tumor Activity Measured by Tumor Shrinkage
Time frame: Baseline to end of trial (Part 1), up to 72 weeks
Part 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Response Evaluation Based on PSA (Prostate Specific Antigen [Prostate Cancer]): Percentage Change From Baseline to End of Study
Time frame: Baseline to end of follow-up; maximum follow-up was 24 weeks
Part 1: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study
Time frame: Baseline to end of follow-up; maximum follow-up was 24 weeks
Part 2: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study
Time frame: Baseline to end of trial (Part 2), up to 36 week
Part 1: Best Overall Response (OR)
Best OR (by investigators assessment) was the best response recorded from the start of the treatment until disease progression or death. Complete response: the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. Based on non-target lesions, complete response was defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Partial response (PR): ≥ 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Based on non-target lesions, stable disease was defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
Time frame: Baseline to end of trial (Part 1), up to 72 weeks
Part 2: Best Overall Response (OR)
Best OR (by investigators assessment) was the best response recorded from the start of the treatment until disease progression or death. Complete response: the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. Based on non-target lesions, complete response was defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Partial response (PR): ≥ 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs. Stable Disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Based on non-target lesions, stable disease was defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Number of Participants Who Experienced Disease Control
Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.
Time frame: 6, 12, 24 and 36 weeks post first infusion (Part 1)
Part 2: Number of Participants Who Experienced Disease Control
Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.
Time frame: 6, 12, 24 and 36 weeks post first infusion (Part 2)
Part 1: Progression Free Survival (PFS)
Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.
Time frame: Baseline to end of follow-up; maximum time of follow-up was 24 weeks
Part 2: Progression Free Survival (PFS)
Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
Part 1: Duration of Response
Duration of response was defined as as the number of days from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the date of first progressive disease (PD) or death.
Time frame: Baseline to end of trial (Part 1), up to 72 weeks
Part 2: Duration of Response
Duration of response was defined as as the number of days from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the date of first progressive disease (PD) or death.
Time frame: Baseline to end of trial (Part 2), up to 36 weeks
For the Dose Escalation, participants took part in the trial at 3 sites located in Denmark, the United Kingdom (UK), and the United States (USA) from 30 Nov 2015 until 10 Feb 2017. Cohort Expansion trial was performed at 10 sites located in Belgium, UK, Denmark, and the USA from 16 Feb 2016 until the last participant visit on 13 Dec 2017.
| Milestone | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Patient choice | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator judgment | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 11 | 3 | 1 | 5 | 1 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Not completed | 0 | 0 | 11 | 3 | 1 | 4 | 1 | 3 |
| Withdrew: Patient choice | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 0 | 3 | 2 | 1 | 4 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 6 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants Who Experience at Least One Adverse Event (AE) | 3 | 6 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants Who Experience at Least One Adverse Event (AE) | 11 | 3 | 1 | 5 | 0 | 3 |
A SAE is defined as an AE that met one or more of the following criteria/outcomes which were classified as serious: Required inpatient hospitalization or prolongation of existing hospitalization. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. Was a congenital anomaly/birth defect. Medically important determined by the investigator. Resulted in death. Was life-threatening.
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE) | 1 | 2 |
A SAE is defined as an AE that met one or more of the following criteria/outcomes which were classified as serious: Required inpatient hospitalization or prolongation of existing hospitalization. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. Was a congenital anomaly/birth defect. Medically important determined by the investigator. Resulted in death. Was life-threatening.
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants Reporting One or More Serious Adverse Events (SAE) | 9 | 2 | 0 | 2 | 0 | 1 |
An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants Reporting One or More Infusion-related Adverse Events | 2 | 4 |
An infusion-related adverse event (AE) was defined as an AE occurring during infusion where the onset date and time of the event occurred within infusion time (+24 hours), and the event was judged as related to tisotumab vedotin by the investigator.
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants Reporting One or More Infusion-related Adverse Events | 4 | 2 | 1 | 1 | 0 | 1 |
A CTCAE AE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator.
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events | 1 | 3 |
A CTCAE AE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator.
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events | 10 | 2 | 0 | 3 | 0 | 1 |
A treatment-related AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; which has a causal relationship with the treatment.
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants Reporting One or More Treatment-related Adverse Events | 3 | 6 |
A treatment-related AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; which has a causal relationship with the treatment.
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events | 9 | 3 | 1 | 5 | 0 | 3 |
The number of participants with any markedly abnormal standard safety laboratory values collected throughout study. Markedly abnormal laboratory values are defined as any grade \>=3 laboratory abnormality events.
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants With Markedly Abnormal Laboratory Values | 0 | 6 |
The number of participants with any markedly abnormal standard safety laboratory values collected throughout study. Markedly abnormal laboratory values are defined as any grade \>=3 laboratory abnormality events.
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With Markedly Abnormal Laboratory Values | 5 | 2 | 0 | 3 | 1 | 3 |
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants Who Experienced a Skin Rash | 0 | 4 |
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants Who Experienced a Skin Rash | 2 | 0 | 1 | 1 | 0 | 1 |
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants Who Experienced a Bleeding Event | 3 | 5 |
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants Who Experienced a Bleeding Event | 7 | 3 | 1 | 5 | 0 | 2 |
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants Who Experienced a Neuropathy Event | 1 | 3 |
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants Who Experienced a Neuropathy Event | 3 | 1 | 0 | 2 | 0 | 1 |
| h*µg/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 3336 ± 7.3 | 5317 ± 34.6 |
| Cycle 1 Day 1 | 867 ± 17.6 | 1328 ± 48.0 |
| Cycle 1 Day 8 | 1603 ± 16.2 | 2216 ± 11.7 |
| Cycle 1 Day 15 | 789 ± 15.6 | 1411 ± 94.2 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| h*µg/mL | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 2267 ± 24.8 | 1755 ± 19.1 | — | — | — | — |
| Cycle 1 Dose 1 | 1889 ± 29.3 | 1412 ± 11.9 | — | — | — | — |
| Cycle 1 Dose 2 | 150 ± 56.2 | 123 ± 85.4 | — | — | — | — |
| Cycle 1 Dose 3 | 410 ± 26.4 | 204 ± 71.3 | — | — | — | — |
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.
| h*µg/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Tisotumab Vedotin (HuMax-TF-ADC) | 920 ± 3.6 | 1106 ± 21.3 |
| µg/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 21.2 ± 14.5 | 30.7 ± 10.1 |
| Cycle 1 Day 1 | 20.2 ± 17.9 | 28.7 ± 12.1 |
| Cycle 1 Day 8 | 20.9 ± 14.1 | 28.0 ± 8.9 |
| Cycle 1 Day 15 | 19.9 ± 11.8 | 26.8 ± 21.6 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| µg/mL | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 28.2 ± 34.5 | 19.5 ± 17.6 | — | — | — | — |
| Cycle 1 Dose 1 | 28.2 ± 34.5 | 19.5 ± 17.6 | — | — | — | — |
| Cycle 1 Dose 2 | 1.00 ± 42.0 | 1.13 ± 112.2 | — | — | — | — |
| Cycle 1 Dose 3 | 3.85 ± 24.5 | 1.85 ± 77.6 | — | — | — | — |
| hours | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 5.864 ± 172.022 | 5.061 ± 166.177 |
| Cycle 1 Day 1 | 0.747 ± 11.547 | 0.873 ± 79.228 |
| Cycle 1 Day 8 | 0.717 ± 0.000 | 0.846 ± 86.481 |
| Cycle 1 Day 15 | 1.141 ± 81.075 | 1.084 ± 73.110 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| hours | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 0.75 ± 68.49 | 0.58 ± 22.85 | — | — | — | — |
| Cycle 1 Dose 1 | 0.75 ± 68.49 | 0.58 ± 22.85 | — | — | — | — |
| Cycle 1 Dose 2 | 165.06 ± 75.01 | 106.93 ± 55.38 | — | — | — | — |
| Cycle 1 Dose 3 | 71.23 ± 24.35 | 80.37 ± 20.24 | — | — | — | — |
Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.
| ng/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 Day 1 | 30.0 ± 0 | 30.0 ± 0 |
| Cycle 1 Day 8 | 797.3 ± 22.1 | 1328.5 ± 191.8 |
| Cycle 1 Day 15 | 912.1 ± 23.7 | 989.0 ± 44.3 |
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore t1/2 could not be determined.
| hours | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Terminal Phase Elimination Half-life (T1/2) for Tisotumab Vedotin (HuMax-TF-ADC) | 40.45 ± 24.78 | 48.15 ± 16.47 |
Data is only available for Part 1, for Part 2 inadequate pharmacokinetic samples were collected after the third dose to define a terminal phase, and therefore CL could not be determined.
| mL/h/kg | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Total Clearance (CL) of Tisotumab Vedotin (HuMax-TF-ADC) | 0.979 ± 3.561 | 1.085 ± 21.476 |
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore Vz could not be determined.
| mL/kg | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Apparent Volume of Distribution (Vz) for Tisotumab Vedotin (HuMax-TF-ADC) | 66.75 ± 6.67 | 75.37 ± 14.89 |
| h*µg/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 3916 ± 7.3 | 5573 ± 15.0 |
| Cycle 1 Day 1 | 1058 ± 15.0 | 1530 ± 34.7 |
| Cycle 1 Day 8 | 1750 ± 16.2 | 2460 ± 8.5 |
| Cycle 1 Day 15 | 1012 ± 25.7 | 1426 ± 28.6 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| h*µg/mL | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 2660 ± 20.0 | 1948 ± 35.2 | — | — | — | — |
| Cycle 1 Dose 1 | 1980 ± 24.5 | 460 ± 84.5 | — | — | — | — |
| Cycle 1 Dose 2 | 299 ± 55.0 | 192 ± 80.9 | — | — | — | — |
| Cycle 1 Dose 3 | 679 ± 25.7 | 291 ± 89.9 | — | — | — | — |
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase.
| h*µg/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Total HuMax-TF (Conjugated and Non-conjugated) | 1268 ± 14.4 | 1594 ± 24.6 |
| µg/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 22.1 ± 9.1 | 31.7 ± 11.9 |
| Cycle 1 Day 1 | 20.3 ± 14.3 | 30.2 ± 34.7 |
| Cycle 1 Day 8 | 21.0 ± 6.3 | 29.2 ± 6.6 |
| Cycle 1 Day 15 | 20.9 ± 12.0 | 29.2 ± 16.2 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| µg/mL | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 27.5 ± 36.4 | 20.6 ± 18.6 | — | — | — | — |
| Cycle 1 Dose 1 | 27.5 ± 36.4 | 20.6 ± 18.6 | — | — | — | — |
| Cycle 1 Dose 2 | 2.00 ± 41.6 | 1.91 ± 105.0 | — | — | — | — |
| Cycle 1 Dose 3 | 6.39 ± 24.6 | 3.68 ± 66.1 | — | — | — | — |
| hours | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 36.445 ± 99.474 | 14.003 ± 117.534 |
| Cycle 1 Day 1 | 0.747 ± 11.547 | 0.893 ± 66.752 |
| Cycle 1 Day 8 | 0.717 ± 0 | 0.869 ± 78.568 |
| Cycle 1 Day 15 | 0.727 ± 4.784 | 0.896 ± 78.665 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| hours | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 0.86 ± 73.61 | 0.58 ± 22.85 | — | — | — | — |
| Cycle 1 Dose 1 | 0.86 ± 73.61 | 0.58 ± 22.85 | — | — | — | — |
| Cycle 1 Dose 2 | 165.06 ± 75.01 | 106 ± 55.38 | — | — | — | — |
| Cycle 1 Dose 3 | 71.23 ± 24.35 | 80.37 ± 20.24 | — | — | — | — |
Data is only available for Part 1, for Part 2 inadequate samples were collected after the third dose to define a terminal phase, and therefore t1/2 could not be determined.
| hours | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Terminal Phase Elimination Half-life (T1/2) for Total HuMax-TF (Conjugated and Non-conjugated) | 49.56 ± 17.35 | 49.34 ± 19.18 |
CL could not be estimated for Part 1 or Part 2 participants due to insufficient number of samples taken.
No measurements were reported for this outcome.
Vz could not be estimated for Part 1 or Part 2 participants due to insufficient number of samples taken.
No measurements were reported for this outcome.
Data is only available for Part 1, for Part 2, inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.
| ng/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 Day 1 | 150.0 ± 0.0 | 150.0 ± 0.0 |
| Cycle 1 Day 8 | 1273.1 ± 23.4 | 1252.2 ± 53.3 |
| Cycle 1 Day 15 | 1625.1 ± 24.4 | 1863.8 ± 46.6 |
| h*ng/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 885 ± 27.1 | 968 ± 59.7 |
| Cycle 1 Day 1 | 185 ± 48.1 | 185 ± 75.3 |
| Cycle 1 Day 8 | 180 ± 14.1 | 236 ± 75.5 |
| Cycle 1 Day 15 | 506 ± 25.3 | 520 ± 51.3 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| h*ng/mL | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 920 ± 74.5 | 1049 ± 89.4 | — | — | — | — |
| Cycle 1 Dose 1 | 439 ± 69.3 | 393 ± 100.0 | — | — | — | — |
| Cycle 1 Dose 2 | 378 ± 121.3 | 366 ± 77.9 | — | — | — | — |
| Cycle 1 Dose 3 | 713 ± 49.9 | 494 ± 121.7 | — | — | — | — |
| ng/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 2.76 ± 23.7 | 2.88 ± 52.4 |
| Cycle 1 Day 1 | 1.46 ± 54.7 | 1.38 ± 78.4 |
| Cycle 1 Day 8 | 1.18 ± 19.8 | 1.54 ± 75.4 |
| Cycle 1 Day 15 | 2.76 ± 23.7 | 2.88 ± 52.4 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| ng/mL | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 3.9 ± 97.0 | 3.6 ± 101.4 | — | — | — | — |
| Cycle 1 Dose 1 | 1.9 ± 110.5 | 1.5 ± 80.4 | — | — | — | — |
| Cycle 1 Dose 2 | 2.47 ± 136.4 | 2.50 ± 81.1 | — | — | — | — |
| Cycle 1 Dose 3 | 3.78 ± 81.6 | 3.23 ± 125.0 | — | — | — | — |
| hours | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 | 392.024 ± 3.256 | 373.366 ± 6.290 |
| Cycle 1 Day 1 | 44.568 ± 114.567 | 32.001 ± 125.788 |
| Cycle 1 Day 8 | 10.354 ± 165.509 | 20.837 ± 106.094 |
| Cycle 1 Day 15 | 54.511 ± 20.424 | 32.537 ± 63.879 |
Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3wk). Data has only been provided for participants who received the original dosing schedule of 3 times every 4 weeks (3q4wk).
| hours | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Cycle 1 | 307.05 ± 36.52 | 410.61 ± 3.82 | — | — | — | — |
| Cycle 1 Dose 1 | 160.56 ± 5.66 | 162.19 ± 1.71 | — | — | — | — |
| Cycle 1 Dose 2 | 164.82 ± 56.71 | 106.93 ± 55.38 | — | — | — | — |
| Cycle 1 Dose 3 | 78.37 ± 50.26 | 80.37 ± 20.24 | — | — | — | — |
Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.
| pg/mL | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Cycle 1 Day 1 | 12.50 ± 0 | 12.50 ± 0 |
| Cycle 1 Day 8 | 853.42 ± 22.93 | 1061.28 ± 87.81 |
| Cycle 1 Day 15 | 1013.22 ± 14.47 | 1384.29 ± 83.43 |
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result | 0 | 0 |
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Number of Patients Who Experienced Anti-tumor Activity Measured by Tumor Shrinkage | 1 | 3 |
| percentage of change | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements | -17.34 ± 43.388 | 32.78 ± 83.933 | -63.27 ± NA | 0.74 ± 21.877 | 0 ± NA | 11.76 ± 27.658 |
| percentage of change | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Response Evaluation Based on PSA (Prostate Specific Antigen [Prostate Cancer]): Percentage Change From Baseline to End of Study | 23.42 ± 61.686 | 12.97 ± NA |
| percentage of change | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study | — | 186.21 ± NA |
| percentage of change | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian |
|---|---|---|---|
| Part 2: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study | -31.75 ± 36.235 | -32.50 ± NA | — |
Best OR (by investigators assessment) was the best response recorded from the start of the treatment until disease progression or death. Complete response: the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. Based on non-target lesions, complete response was defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Partial response (PR): ≥ 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Based on non-target lesions, stable disease was defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
| participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 0 | 1 |
| Stable Disease | 2 | 3 |
| Progressive Disease | 1 | 1 |
| Not Evaluable | 0 | 1 |
Best OR (by investigators assessment) was the best response recorded from the start of the treatment until disease progression or death. Complete response: the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. Based on non-target lesions, complete response was defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Partial response (PR): ≥ 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs. Stable Disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Based on non-target lesions, stable disease was defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
| participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial Response | 3 | 1 | 1 | 2 | 0 | 0 |
| Stable Disease | 3 | 0 | 0 | 2 | 0 | 2 |
| Progressive Disease | 2 | 2 | 0 | 1 | 1 | 1 |
| Not Evaluable | 3 | 0 | 0 | 0 | 0 | 0 |
Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.
| Participants | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| 6 Weeks — Disease Control - Yes | 2 | 3 |
| 6 Weeks — Disease Control - No | 1 | 3 |
| 12 Weeks — Disease Control - Yes | 0 | 0 |
| 12 Weeks — Disease Control - No | 3 | 6 |
| 24 Weeks — Disease Control - Yes | 0 | 0 |
| 24 Weeks — Disease Control - No | 3 | 6 |
| 36 Weeks — Disease Control - Yes | 0 | 0 |
| 36 Weeks — Disease Control - No | 3 | 6 |
Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.
| Participants | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| 6 Weeks — Disease Control - Yes | 6 | 1 | 1 | 4 | 0 | 2 |
| 6 Weeks — Disease Control - No | 5 | 2 | 0 | 1 | 1 | 1 |
| 12 Weeks — Disease Control - Yes | 2 | 1 | 1 | 2 | 0 | 1 |
| 12 Weeks — Disease Control - No | 9 | 2 | 0 | 3 | 1 | 2 |
| 24 Weeks — Disease Control - Yes | 0 | 0 | 0 | 1 | 0 | 0 |
| 24 Weeks — Disease Control - No | 11 | 3 | 1 | 4 | 1 | 3 |
| 36 Weeks — Disease Control - Yes | 0 | 0 | 0 | 0 | 0 | 0 |
| 36 Weeks — Disease Control - No | 11 | 3 | 1 | 5 | 1 | 3 |
Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.
| weeks | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg |
|---|---|---|
| Part 1: Progression Free Survival (PFS) | 11.3 (7.3 to 15.3) | NA (7.1 to NA) |
Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.
| weeks | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|
| Part 2: Progression Free Survival (PFS) | 10.7 (2.0 to NA) | 8.0 (4.3 to NA) | 22.0 (NA to NA) | 14.0 (9.1 to NA) | 5.0 (NA to NA) | 11.9 (11.0 to 17.1) |
Duration of response was defined as as the number of days from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the date of first progressive disease (PD) or death.
No measurements were reported for this outcome.
Duration of response was defined as as the number of days from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the date of first progressive disease (PD) or death.
No measurements were reported for this outcome.
Collected over Part 1: Dose Escalation: Baseline to follow-up; maximum time of follow-up was 24 weeks. Part 2: Cohort Expansion: Baseline to a maximum of 36 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | 1/11 (9.1%) | 9/11 (81.8%) | 10/11 (90.9%) |
| Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|---|---|
| SymblepharonEye disorders | 0/3 | 0/6 | 4/11 | 1/3 | 0/1 | 0/5 | 0/1 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/6 | 0/11 | 0/3 | 0/1 | 0/5 | 0/1 | 1/3 |
| ConjunctivitisInfections and infestations | 1/3 | 0/6 | 3/11 | 1/3 | 0/1 | 0/5 | 0/1 | 0/3 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/6 | 0/11 | 1/3 | 0/1 | 0/5 | 0/1 | 0/3 |
| GastroenteritisInfections and infestations | 0/3 | 0/6 | 0/11 | 0/3 | 0/1 | 0/5 | 0/1 | 1/3 |
| Colonic pseudo-obstructionGastrointestinal disorders | 0/3 | 0/6 | 0/11 | 0/3 | 0/1 | 1/5 | 0/1 | 0/3 |
| HyponatraemiaMetabolism and nutrition disorders | 0/3 | 1/6 | 0/11 | 0/3 | 0/1 | 1/5 | 0/1 | 0/3 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/3 | 0/6 | 0/11 | 0/3 | 0/1 | 1/5 | 0/1 | 0/3 |
| NauseaGastrointestinal disorders | 0/3 | 1/6 | 1/11 | 0/3 | 0/1 | 0/5 | 0/1 | 0/3 |
| VomitingGastrointestinal disorders | 0/3 | 1/6 | 1/11 | 0/3 | 0/1 | 0/5 | 0/1 | 0/3 |
| Event | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 2/6 | 5/11 | 1/3 | 1/1 | 1/5 | 0/1 | 0/3 |
| Abdominal painGastrointestinal disorders | 0/3 | 3/6 | 4/11 | 0/3 | 1/1 | 3/5 | 0/1 | 0/3 |
| Lip ulcerationGastrointestinal disorders | 0/3 | 0/6 | 0/11 | 0/3 | 1/1 | 0/5 | 0/1 | 0/3 |
| ConjunctivitisInfections and infestations | 2/3 | 6/6 | 5/11 | 0/3 | 0/1 | 3/5 | 0/1 | 1/3 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/3 | 5/6 | 7/11 | 1/3 | 1/1 | 3/5 | 0/1 | 2/3 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/3 | 0/6 | 1/11 | 0/3 | 1/1 | 1/5 | 0/1 | 0/3 |
| FatigueGeneral disorders | 2/3 | 2/6 | 6/11 | 1/3 | 1/1 | 4/5 | 0/1 | 2/3 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 3/6 | 5/11 | 1/3 | 1/1 | 1/5 | 0/1 | 0/3 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/3 | 1/6 | 5/11 | 1/3 | 1/1 | 3/5 | 0/1 | 2/3 |
| PruritusSkin and subcutaneous tissue disorders | 0/3 | 1/6 | 1/11 | 1/3 | 1/1 | 1/5 | 0/1 | 0/3 |
| Age, Customized(Participants) | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adults (18-64 years) | 0 | 3 | 10 | 3 | 1 | 4 | 1 | 3 | 25 |
| From 65 to 84 years | 3 | 3 | 1 | 0 | 0 | 1 | 0 | 0 | 8 |
| Sex: Female, Male(Participants) | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 4 | 11 | 3 | 1 | 5 | 1 | 3 | 29 |
| Male | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 3 | 6 | 10 | 3 | 1 | 5 | 1 | 3 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 5 | 10 | 3 | 1 | 5 | 1 | 3 | 31 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | Total |
|---|---|---|---|---|---|---|---|---|---|
| Belgium | 0 | 0 | 6 | 3 | 0 | 2 | 0 | 2 | 13 |
| United States | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 4 |
| Denmark | 2 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 5 |
| United Kingdom | 1 | 1 | 4 | 0 | 1 | 2 | 1 | 1 | 11 |
| Weight(kg) | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | Total |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Dose Escalation | 80.0 (76.3 to 80.0) | 67.5 (48.1 to 85.0) | — | — | — | — | — | — | 74.7 (48.1 to 85.0) |
| Part 2: Cohort Expansion | — | — | 66.8 (40.0 to 89.6) | 55.2 (41.7 to 63.5) | 57.8 (57.8 to 57.8) | 72.0 (52.8 to 79.3) | 96.8 (96.8 to 96.8) | 65.3 (60.5 to 65.5) | 64.8 (40.0 to 96.8) |
| Height(cm) | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | Total |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Dose Escalation | 171.0 (168.0 to 171.4) | 162.0 (156.0 to 175.0) | — | — | — | — | — | — | 168.0 (156.0 to 175.0) |
| Part 2: Cohort Expansion | — | — | 159.0 (154.0 to 174.0) | 157.0 (148.0 to 161.0) | 160.6 (160.6 to 160.6) | 168.0 (159.0 to 177.8) | 170.5 (170.5 to 170.5) | 161.0 (156.0 to 162.0) | 160.8 (148.0 to 177.8) |
| Body Mass Index (BMI)(kg/m^2) | Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg | Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg | Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian | Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical | Part 2 Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical | Part 2 Cohort Expansion: Cohort 5 1q3w Ovarian | Part 2: Cohort Expansion: Cohort 6 1q3w Cervical | Total |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Dose Escalation | 27.4 (26.0 to 28.3) | 25.5 (19.8 to 27.8) | — | — | — | — | — | — | 25.7 (19.8 to 28.3) |
| Part 2: Cohort Expansion | — | — | 26.4 (16.9 to 32.5) | 22.4 (16.1 to 29.0) | 22.4 (22.4 to 22.4) | 24.0 (18.7 to 28.5) | 33.3 (33.3 to 33.3) | 24.9 (23.3 to 26.9) | 25.1 (16.1 to 33.3) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Dec 2017, 24 months.
Results were first posted in Mar 2019, 1 year 2 months after primary completion.
Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's 24 months is below that.
Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tisotumab vedotin